Show simple item record

dc.contributor.authorSo, E.C.
dc.contributor.authorKhaladj-Ghom, A.
dc.contributor.authorJi, Y.
dc.date.accessioned2019-03-29T14:47:36Z
dc.date.available2019-03-29T14:47:36Z
dc.date.issued2019
dc.identifier.urihttps://www.scopus.com/inward/record.uri?eid=2-s2.0-85062614552&doi=10.1016%2fj.imbio.2019.03.001&partnerID=40&md5=9375047a9b12e1068ef501eee03ecf69
dc.identifier.urihttp://hdl.handle.net/10713/8688
dc.description.abstractGiven the heightened interest in manipulation of co-signaling cascades for cancer immunotherapy, we sought to determine how/whether tumors decorated with therapeutic monoclonal antibodies (mAbs) impact the expression of co-signaling molecules on human NK cells. Stimulation of NK cells with aggregated IgG1 resulted in the upregulation of HAVCR2 - the gene encoding T-cell immunoglobulin and mucin-containing domain (Tim)-3 - known to be involved in the induction of peripheral T cell tolerance. This upregulation of HAVCR2 was recapitulated at the protein level, following NK cell stimulation by either mAb opsonized tumors, recombinant human IgG1 Fc multimer, and/or non-Fc stimuli e.g. IL-12/IL-18. The patterns of Tim-3 expression were temporally distinct from the FcR mediated induction of the co-signaling molecule, 4-1BB (CD137), with Tim-3 increases observed twenty minutes following exposure to Fc multimers and remaining at high levels for at least six hours, while increases in CD137 expression were first observed at the four-hour time point. Importantly, these Tim-3+ NK cells were functionally diverse, as evidenced by the fact that their ability to produce IFN-γ in response to an NK cell responsive tumor was strictly dependent upon the stimuli employed for Tim-3 induction. These data suggest that Tim-3 upregulation is the common end-result of NK cell activation by a variety of unique and overlapping stimuli and is not an independent marker of NK cell exhaustion. Furthermore, our observations potentially explain the diverse functionality attributed to Tim-3+ NK cells and should be considered prior to use of anti-Tim-3 inhibitory mAbs for cancer immunotherapy. © 2019 The Authorsen_US
dc.description.sponsorshipDr. Strome is a Cofounder, consultant and stockholder in Gliknik Inc., a biotechnology company. He receives royalties for intellectual property, related to B7-H1 (PD-L1), licensed by the Mayo Clinic College of Medicine to third parties. He receives research support from Pfizer and Gliknik through sponsored research agreements through the University of Maryland, Baltimore. He serves on the scientific advisory board of Virion Inc. and has also served on Advisory Boards to Astra Zeneca and Genentech.en_US
dc.description.urihttps://dx.doi.org/10.1016/j.imbio.2019.03.001en_US
dc.language.isoen_USen_US
dc.publisherElsevier GmbHen_US
dc.relation.ispartofImmunobiology
dc.subjectAntibody stimulationen_US
dc.subjectCD137en_US
dc.subjectFc multimersen_US
dc.subjectFc receptorsen_US
dc.subjectNatural killer cellsen_US
dc.subjectTim-3en_US
dc.titleNK cell expression of Tim-3: First impressions matteren_US
dc.typeArticleen_US
dc.identifier.doi10.1016/j.imbio.2019.03.001


Files in this item

Thumbnail
Name:
Publisher version

This item appears in the following Collection(s)

Show simple item record